



NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: HIV-1 PTE Gag Peptide Pool

Catalog Number: 12437

Lot Number: 170369

Provided: 1 vial of lyophilized peptides

The 320 peptides from cat# 11554 peptide set were pooled together and then distributed such that each vial contains 50 µg of each peptide, 16 mg total peptide.

Description: This peptide pool is designed to represent the most frequent potential T cell epitopes (PTE) of HIV-1 Gag embedded in the sequences of circulating strains of HIV-1 worldwide. The peptides are 15 a.a. in length and contain naturally occurring 9 a.a. sequences that are potential T cell determinants, captured in an unbiased manner.

Also available as a peptide pool, see HIV-1 PTE Gag Peptide Set, cat# 11554.

Purity: Peptides are >80% pure. Detailed purity information is available in the attached file below.

Solubility: Peptides that are difficult to solubilize can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution.

Please note: Cys and Met containing peptide sequences are highly unstable when stored in DMSO for prolonged periods of time; peptide decay is often observed within days to weeks. If DMSO is required, we recommend freshly-prepared working solutions from freeze dried aliquots of these peptides, and prepared pools.

Special Characteristics: [Click here for cat# 11554 \(set\) and cat# 12437 \(pool\) sequence, molecular weight, peptide content, and purity data](#)

[Click here for individual peptide analytical data](#)

Please Note: The peptides are listed in the order of decreasing frequency.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage: Keep the reagent at -20°C lyophilized and -80°C after reconstitution.

Contributor: NIAID, DAIDS

References: Li, F., Malhotra, U., Gilbert, P. B., Hawkins, N. R., Duerr, A. C., McElrath, J. M., . . . Self, S. G. (2006). Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. *Vaccine*, 24(47-48), 6893-6904. doi:10.1016/j.vaccine.2006.06.009 [PUBMED](#)

Malhotra, U., Li, F., Nolin, J., Allison, M., Zhao, H., Mullins, J. I., . . . McElrath, M. J. (2007). Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection. *J Virol*, 81(10), 5225-5237. doi:10.1128/JVI.02564-06 [PUBMED](#)

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 PTE Gag Peptide Pool from NIAID, DAIDS (cat #12437).

Last Updated: October 09, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.